{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:24:06Z","timestamp":1779243846894,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016726","name":"Fondazione Aviralia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jcv.2020.104534","type":"journal-article","created":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T01:44:06Z","timestamp":1594518246000},"page":"104534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings"],"prefix":"10.1016","volume":"130","author":[{"given":"Daniele","family":"Armenia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yagai","family":"Bouba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanni","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-3875","authenticated-orcid":false,"given":"Valeria","family":"Micheli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Paola","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Gazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Giannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Vergori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Mastrorosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Colafigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Lichtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-5089","authenticated-orcid":false,"given":"Antonio","family":"di Biagio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Maggiolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliano","family":"Rizzardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"d\u2019Arminio Monforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2020.104534_bib0005","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/phar.2246","article-title":"Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?","volume":"39","author":"Brooks","year":"2019","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.jcv.2020.104534_bib0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.jcv.2020.104534_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.JAA.0000475465.07971.19","article-title":"HIV pharmacotherapy: a review of integrase inhibitors","volume":"29","author":"Wong","year":"2016","journal-title":"JAAPA"},{"key":"10.1016\/j.jcv.2020.104534_bib0020","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1517\/14656566.2015.1044436","article-title":"HIV integrase inhibitors: a new era in the treatment of HIV","volume":"16","author":"Blanco","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jcv.2020.104534_bib0025","series-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2020"},{"key":"10.1016\/j.jcv.2020.104534_bib0030","series-title":"Guidelines Version 10.0","author":"European AIDS Clinical Society (EACS)","year":"2019"},{"key":"10.1016\/j.jcv.2020.104534_bib0035","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1060028013513558","article-title":"Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection","volume":"48","author":"Rathbun","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jcv.2020.104534_bib0040","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/jac\/dkz021","article-title":"Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients","volume":"74","author":"Marcelin","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2020.104534_bib0045","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104534_bib0050","first-page":"59","article-title":"Genetic barrier to resistance for dolutegravir","volume":"17","author":"Llibre","year":"2014","journal-title":"AIDS Rev."},{"key":"10.1016\/j.jcv.2020.104534_bib0055","first-page":"8","article-title":"Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen","author":"Armenia","year":"2019","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2020.104534_bib0060","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3851\/IMP3197","article-title":"VIRO-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia &500,000 copies\/ml in clinical practice","volume":"23","author":"Santoro","year":"2018","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2020.104534_bib0065","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3851\/IMP2531","article-title":"Impact of pre-therapy viral load on virological response to modern irst-line HAART","volume":"18","author":"Santoro","year":"2013","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2020.104534_bib0070","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/jac\/dkz067","article-title":"Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice","volume":"74","author":"Alvarez","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2020.104534_bib0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jiw165","article-title":"Successful prevention of transmission of integrase resistance in the swiss HIV cohort study","volume":"214","author":"Scherrer","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104534_bib0080","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1128\/AAC.00397-09","article-title":"Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors","volume":"53","author":"Low","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jcv.2020.104534_bib0085","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/jac\/dkv202","article-title":"Primary resistance to integrase strand-transfer inhibitors in Europe","volume":"70","author":"Casadell\u00e0","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2020.104534_bib0090","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1038\/s41598-018-22914-5","article-title":"Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and availability of integrase inhibitors in Cape Town, South Africa OPEN","volume":"8","author":"Brado","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jcv.2020.104534_bib0095","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/ciu020","article-title":"Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels","volume":"58","author":"Santoro","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104534_bib0100","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/jac\/dkv029","article-title":"HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia","volume":"70","author":"Armenia","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2020.104534_bib0105","first-page":"19","article-title":"Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: a systematic review and network meta-analysis","author":"Snedecor","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jcv.2020.104534_bib0110","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013016","article-title":"Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-na\u00efve human immunodeficiency virus\u2013infected patients compared to non-nucleoside and protease inhibitor\u2013based regimens in a real-world clinical setting","volume":"97","author":"Jacobson","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jcv.2020.104534_bib0115","first-page":"15","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.jcv.2020.104534_bib0120","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3851\/IMP2736","article-title":"Effectiveness of efavirenz compared with ritonavirboosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies\/ml","volume":"19","author":"Imaz","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2020.104534_bib0125","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2019.08.008","article-title":"Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors","volume":"54","author":"Yang","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jcv.2020.104534_bib0130","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3851\/IMP2885","article-title":"Week 144 resistance analysis of elvitegravir\/ cobicistat\/emtricitabine\/tenofovir DF versus efavirenz\/emtricitabine\/tenofovir DF in antiretroviral-naive patients","volume":"20","author":"White","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jcv.2020.104534_bib0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/hiv.12388","article-title":"Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens","volume":"18","author":"Armenia","year":"2017","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2020.104534_bib0140","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1093\/jac\/dky211","article-title":"Impact of transmitted HIV-1 drug resistance on the efficacy of firstline antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor","volume":"73","author":"Raffaelli","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2020.104534_bib0145","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/jac\/dkx511","article-title":"Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen","volume":"73","author":"Charpentier","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2020.104534_bib0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/QAD.0000000000001679","article-title":"Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors","volume":"32","author":"Cid-Silva","year":"2018","journal-title":"AIDS"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653220302766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653220302766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T23:57:32Z","timestamp":1748649452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653220302766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":30,"alternative-id":["S1386653220302766"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2020.104534","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2020.104534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104534"}}